- Home
- RIGL vs NVRI Comparison
RIGL vs NVRI Comparison
Compare RIGL & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- NVRI
- Stock Information
- Founded
- RIGL 1996
- NVRI 1853
- Country
- RIGL United States
- NVRI United States
- Employees
- RIGL N/A
- NVRI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- NVRI Diversified Commercial Services
- Sector
- RIGL Health Care
- NVRI Miscellaneous
- Exchange
- RIGL Nasdaq
- NVRI Nasdaq
- Market Cap
- RIGL 486.4M
- NVRI 572.2M
- IPO Year
- RIGL 2000
- NVRI N/A
- Fundamental
- Price
- RIGL $17.09
- NVRI $7.65
- Analyst Decision
- RIGL Buy
- NVRI Hold
- Analyst Count
- RIGL 5
- NVRI 1
- Target Price
- RIGL $34.80
- NVRI $10.00
- AVG Volume (30 Days)
- RIGL 203.8K
- NVRI 998.5K
- Earning Date
- RIGL 11-07-2024
- NVRI 10-31-2024
- Dividend Yield
- RIGL N/A
- NVRI N/A
- EPS Growth
- RIGL N/A
- NVRI N/A
- EPS
- RIGL 0.22
- NVRI N/A
- Revenue
- RIGL $157,374,000.00
- NVRI $2,086,473,000.00
- Revenue This Year
- RIGL $48.98
- NVRI $16.52
- Revenue Next Year
- RIGL $14.43
- NVRI $0.21
- P/E Ratio
- RIGL $77.18
- NVRI N/A
- Revenue Growth
- RIGL 21.65
- NVRI N/A
- 52 Week Low
- RIGL $7.48
- NVRI $6.57
- 52 Week High
- RIGL $29.82
- NVRI $12.79
- Technical
- Relative Strength Index (RSI)
- RIGL 30.82
- NVRI 50.28
- Support Level
- RIGL $16.68
- NVRI $7.55
- Resistance Level
- RIGL $19.80
- NVRI $7.83
- Average True Range (ATR)
- RIGL 1.53
- NVRI 0.27
- MACD
- RIGL -1.05
- NVRI 0.05
- Stochastic Oscillator
- RIGL 3.66
- NVRI 65.83
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.